Trial Profile

Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Degarelix (Primary) ; Enzalutamide (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary)
Indications Prostate cancer
Focus Therapeutic Use

16 Jul 2025 Status changed from active, no longer recruiting to completed.
30 Apr 2025 Results assessing acute effects of AR inhibition in hormone-sensitive mPC to identify therapeutic targets to prevent resistance, presented at the 116th Annual Meeting of the American Association for Cancer Research.
06 Oct 2020 Results evaluating prostate multiparametric MRI (mpMRI) before and after neoadjuvant enzalutamide plus ADT, published in the Clinical Cancer Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com